GlobeNewsWire
15 Oct 2025, 19:39 UTC · 48w ago
Verdict
Headline leans bearish. We score MLTX −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
MoonLake's sole drug candidate, sonelokimab (SLK), failed to demonstrate competitive efficacy relative to BIMZELX in its Phase 3 VELA program results.
More negative than 99% of claims this week
MoonLake Immunotherapeutics' stock price declined nearly 90% following the announcement of the Phase 3 VELA program results on September 28, 2025.
So whatA massive price collapse indicates a total loss of investor confidence and a severe devaluation of the company's market cap.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 98% of claims this week
A class action lawsuit (Bridgewood v. MoonLake Immunotherapeutics) has been filed alleging that the company made misleading statements regarding SLK's clinical benefits and tissue penetration.
More negative than 81% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a class action lawsuit following a 90% stock price drop due to failed Phase 3 trial results.
More negative than 80% of ticker scores this week
The law firm is investigating whether the company and its executives made materially false or misleading statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
+22.2%
Price is moving against the score
$12.39 vs $10.14 close before publication (Oct 14) · not market-adjusted
MLTX chart →
